News
Press release
01/07/2022
ONCODESIGN announces the separation of its two business lines – Service and Biotech
ONCODESIGN today announced that the Board of Directors has approved the subsidiarisation of its Biotech business.
News
11/04/2022
Parkinson’s Disease: Growing Prevalence And Continued Significant Medical Need
Explore the disease & find out about our strategic R&D collaboration with Servier: info, press releases & video!
Press release
24/02/2022
Abzena, Alira Health and Oncodesign launch DRIVE-Biologics to support access to specialist services
Abzena x Alira Health x Oncodesign: unveil unique integrated solution with specialist services, from biologics discovery to clinical & commercial manufacturing
Press release
08/02/2022
SEngine Precision Medicine & Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment
Read all the details of the collaboration agreement for R&D of a new personalized cancer treatment for aggressive and untreatable tumors.
Press release
04/11/2021
ONCODESIGN strengthens the intellectual property of ODS 101 in treating inflammatory bowel disease
Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia
News
28/10/2021
Oncodesign: EHDEN Certified SME
EHDEN network will enable transparent & fully reproducible research by standardizing both the health data & the analytical pipeline.
Press release
25/10/2021
Oncodesign has appointed Karine Lignel as Group Chief Development Officer
Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.
Press release
21/10/2021
Oncodesign and TiumBio sign collaboration agreement for R&D of fibrosis drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.
Press release
05/07/2021
Oncodesign announces the appointment of Aline Aubertin as an independent director of the Board of Directors
Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director.
News
02/07/2021
Our brand Oncodesign
Our brand Oncodesign . Combination of the words oncology and design... Precision Medicine for patient... Oncodesign Services
News
02/07/2021
Find out how we built our logo!
Oncodesign Services Find out how we built our logo! trajectory DNA innovation...green and bleue pharma colors Find out how we built our logo!
Press release
01/07/2021
Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT
Discover the alliance of experts in radiopharmaceuticals: an innovative offer in therapeutic development in nuclear medicine from the validation of therapeutic targets, the generation of radiolabeled biological vectors, the optimization of leads, the generation of drug candidates to IND, the design and management of clinical trials.